Pediatric Studies Of Clolar, Neulasta, Kepivance To Be Discussed By Oncology Subcommittee
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme and Amgen will share their challenges in design and implementation of post-marketing pediatric studies, such as patient accrual problems and changes in standard of care, at FDA's Oncologic Drugs Advisory Committee on Oct. 20.